Table 1.
Clinicopathological and treatment characteristics of patients with low- or high-risk KRAS mutations who underwent liver resection for colorectal liver metastases
| Wild-type (n = 1005) | High risk (n = 254) | Low risk (n = 308) | P† | |
|---|---|---|---|---|
| Age (years)* | 61.2 (53.0–68.9) | 63.0 (55.0–71.0) | 62.0 (54.0–71.0) | 0.031‡ |
| Sex | 0.056 | |||
| M | 357 (36) | 109 (43) | 124 (40) | |
| F | 647 (64) | 145 (57) | 184 (60) | |
| T3–4 primary tumour | 0.179 | |||
| No | 125 (13) | 42 (18) | 39 (13) | |
| Yes | 838 (87) | 198 (82) | 259 (87) | |
| Primary lymph node status | 0.014 | |||
| Negative | 338 (34) | 106 (43) | 124 (41) | |
| Positive | 646 (66) | 142 (57) | 179 (59) | |
| Primary tumour location | <0.001 | |||
| Right colon | 224 (22) | 93 (37) | 125 (41) | |
| Left colon | 422 (42) | 85 (34) | 72 (24) | |
| Rectum | 352 (35) | 73 (29) | 107 (35) | |
| Synchronous CRLM | 0.724 | |||
| No | 426 (49) | 111 (49) | 142 (51) | |
| Yes | 449 (51) | 115 (51) | 134 (49) | |
| CEA (ng/mL)* | 7.1 (3.1–23.0) | 7.6 (3.5–29.2) | 9.1 (3.6–25.8) | 0.117‡ |
| Tumour size (cm)* | 2.5 (1.6–4.0) | 2.4 (1.5–3.7) | 2.5 (1.5–3.9) | 0.425‡ |
| Chemotherapy before hepatic resection | 0.221 | |||
| No | 383 (38) | 111 (44) | 125 (41) | |
| Yes | 621 (62) | 142 (56) | 181 (59) | |
| Extrahepatic disease | 0.502 | |||
| No | 896 (89) | 221 (87) | 269 (87) | |
| Yes | 109 (11) | 33 (13) | 39 (13) | |
| No of tumours* | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | 0.619‡ |
| Bilobar disease | 0.094 | |||
| No | 621 (62) | 174 (69) | 201 (66) | |
| Yes | 376 (38) | 77 (31) | 105 (34) | |
| Intraoperative concurrent ablation | 0.084 | |||
| No | 787 (88) | 184 (82) | 239 (86) | |
| Yes | 110 (12) | 40 (18) | 40 (14) | |
| R0 resection | 0.013 | |||
| No | 729 (74) | 201 (81) | 239 (80) | |
| Yes | 258 (26) | 46 (19) | 61 (20) | |
| Adjuvant chemotherapy | 0.001 | |||
| No | 491 (51) | 105 (46) | 110 (39) | |
| Yes | 473 (49) | 123 (54) | 173 (61) | |
| Recurrence-free survival | 0.006 | |||
| 1 year | 354 (36) | 76 (31) | 78 (26) | |
| 3 years | 642 (64) | 172 (69) | 222 (74) | |
| Site of recurrence | <0.001 | |||
| Intrahepatic | 301 (51) | 55 (39) | 66 (32) | |
| Extrahepatic | 170 (29) | 45 (32) | 72 (35) | |
| Both | 122 (21) | 42 (30) | 66 (32) |
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). CRLM, colorectal liver metastasis; CEA, carcinoembryonic antigen. †χ2 or Fisher’s exact test, except ‡Mann Whitney U test.